The regulation and function of the Forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma

Endocrinology

Volumn 149, Issue 4, 2008, Pages 1942-1950

  Ward, Erin C ^a   Hoekstra, Anna V ^a   Blok, Leen J ^b   Hanifi Moghaddam, P ^b   Lurain, John R ^a   Singh, Diljeet K ^a   Buttin, Barbara M ^a   Schink, Julian C ^a   Kim, J Julie ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; MESSENGER RNA; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; PROMEGESTONE; PROTEIN KINASE B; S PHASE KINASE ASSOCIATED PROTEIN 2; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FOXO;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, PROGESTERONE; S-PHASE KINASE-ASSOCIATED PROTEINS;

EID: 41549098778     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2007-0756     Document Type: Article

References (46)

1. Ryan A, Susil B, Jobling T, Oehler M 2005 Endometrial cancer. Cell Tissue Res 322:53-61
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ 2007 Cancer statistics, 2007. CA Cancer J Clin 57:43-66
3. Hecht J, Mutter G 2006 Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 24:4783-4791
4. Kau T, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, Roberts TM, Clardy J, Sellers WR, Silver PA 2003 A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 4:463-476
5. Brazil DP, Yang ZZ, Hemmings BA 2004 Advances in protein kinase B signaling: AKTion on multiple fronts. Trends Biochem Sci 29:233-242
6. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME 1999 Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857-868
7. Tang ED, Nunez G, Barr FG, Guan KL 1999 Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem 274:16741-16746
8. Biggs WH, Meisenhelder J, Hunter T, Cavenee WK, Arden KC 1999 Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA 96:7421-7426
9. Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, Burgering BM 1999 Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 398:630-634
10. Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM, Tindall DJ 2005 Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci USA 102:1649-1654
11. Grinius L, Kessler C, Schroeder J, Handwerger S 2006 Forkhead transcription factor FOXO1 is critical for induction of human decidualization. J Endocrinol 189:179-187
12. Alikhani M, Alikhani Z, Graves D 2005 FOXO1 functions as a master switch that regulates gene expression necessary for tumor necrosis factor-induced fibroblast apoptosis. J Biol Chem 280:12096-12102
13. Buzzio OL, Lu Z, Miller CD, Unterman TG, Kim JJ 2006 FOXO1 differentially regulates genes of decidualization. Endocrinology 147:3870-3876
14. Christian M, Zhang X, Schneider-Merck T, Unterman TG, Gellersen B, White JO, Brosens JJ 2002 Cyclic AMP-induced forkhead transcription factor, FKHR, cooperates with CCAAT/enhancer-binding protein β in differentiating human endometrial stromal cells. J Biol Chem 277:20825-20832
15. Takano M, Lu Z, Goto T, Fusi L, Higham J, Francis J, Withey A, Hardt J, Cloke B, Stavropoulou AV, Ishihara O, Lam EW, Unterman TG, Brosens JJ, Kim JJ 2007 Transcriptional cross talk between the forkhead transcription factor forkhead box O1A and the progesterone receptor coordinates cell cycle regulation and differentiation in human endometrial stromal cells. Mol Endocrinol 21:2334-2349
16. Labied S, Kajihara T, Madureira P, Fusi L, Jones MC, Higham JM, Varshochi R, Francis JM, Zoumpoulidou G, Essafi A, Fernandez de Mattos S, Lam EW, Brosens JJ 2006 Progestins regulate the expression and activity of the forkhead transcription factor FOXO1in differentiating human endometrium. Mol Endocrinol 20:35-44
17. Kim JJ, Jaffe RC, Fazleabas AT 1998 Comparative studies on the in vitro decidualization process in the baboon (Papio anubis) and human. Biol Reprod 59:160-168
18. Hanekamp EE, Kuhne LM, Grootegoed JA, Burger CW, Blok LJ 2004 Progesterone receptor A and B expression and progestagen treatment in growth and spread of endometrial cancer cells in nude mice. Endocr Relat Cancer 11:831-841
19. Nawaz Z, Lonard DM, Smith CL, Lev-Lehman E, Tsai SY, Tsai MJ, O'Malley BW 1999 The Angelman syndrome-associated protein, E6-AP is a coactivator for the nuclear hormone receptor superfamily. Mol Cell Biol 9:1182-1189
20. Guo S, Rena G, Cichy S, He X, Cohen P, Unterman T 1999 Phosphorylation of serine 256 protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence. J Biol Chem 274:17184-17192
21. Kamata Y, Watanabe J, Nishimura Y, Arai T, Kawaguchi M, Hattori M, Obokata A, Kuramoto H 2005 High expression of skp2 correlates with poor prognosis in endometrial endometrioid adenocarcinoma. J Cancer Res Clin Oncol 131:591-596
22. Carrano AC, Eytan E, Hershko A, Pagano M 1999 Skp2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1:193-199
23. Giatromanolaki A, Koukourakis MI, Sivridis E, Gatter KC, Harris AL, Banham AH 2006 Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1α expression. Mod Pathol 19:9-16
24. Goto T, Takano M, Albergaria A, Briese J, Pomeranz KM, Cloke B, Fusi L, Feroze-Zaidi F, Maywald N, Sajin M, Dina RE, Ishihara O, Takeda S, Lam EW, Bamberger AM, Ghaem-Maghami S, Brosens JJ 2008 Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. Oncogene 27:9-19
25. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR 2000 Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 20:8969-8982
26. Accili D, Arden KC 2004 FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 177:421-426
27. Furukawa-Hibi Y, Kobayashi Y, Chen C, Motoyama N 2005 FOXO transcription factors in cell-cycle regulation and the response to oxidative stress. Antioxid Redox Signal 7:752-760
28. Vogt PK, Jiang H, Aoki M 2005 Triple layer control: phosphorylation, acetylation, and ubiquitination of FOXO proteins. Cell Cycle 4:908-913
29. Aoki M, Jiang H, Vogt PK 2004 Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc Natl Acad Sci USA 101:13613-13617
30. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, Kobayashi R, Hung MC 2004 IκB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117:225-237
31. Quarmny VE, Korach KS 1984 The influence of 17β-estradiol on patterns of cell division in the uterus. Endocrinology 114:694-702
32. Martin L, Das RM, Finn CA 1973 The inhibition by progesterone of uterine epithelial proliferation in the mouse. J Endocrinol 57:549-554
33. Ehrlich CE, Young PC, Cleary RE 1981 Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications. Am J Obstet Gynecol 141:539-546
34. Savouret JF, Rauch M, Redeuilh G, Sar S, Chauchereau A, Woodruff K, Parker MG, Milgrom E 1994 Interplay between estrogens, progestins, retinoic acid and AP-1 on a single regulatory site in the progesterone receptor gene. J Biol Chem 269:28955-28962
35. Johansson ED, Jonasson LE 1971 Progesterone levels in amniotic fluid and plasma from women. I. Levels during normal pregnancy. Acta Obstet Gynecol Scand 50:339-343
36. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, Soper JT, Given FT 1999 Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17:1736-1744
37. Giangrande PH, McDonnell DP 1999 The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Recent Prog Horm Res 54:291-314
38. Smid-Koopman E, Blok L, Kuhne LC, Burger CW, Helmerhorst TJ, Brinkmann AO, Huikeshoven FJ 2003 Distinct functional differences of human progesterone receptors A and B on gene expression and growth regulation in two endometrial carcinoma cell lines. J Soc Gynecol Investig 10:49-57
39. Jacobsen BM, Schittone SA, Richer JK, Horwitz KB 2005 Progesterone-induced effects of human progesterone receptors (PRs) in estrogen receptorpositive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol 19:574-587
40. Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz AP, Ngan HY, Sideri M, Pecorelli S 2001 Carcinoma of the corpus uteri. J Epidemiol Biostat 6:47-86
41. Southcott BM 2001 Carcinoma of the endometrium. Drugs 61:1395-1405
42. Fujimoto J, Ichigo S, Hori M, Nishigaki M, Tamaya T 1995 Expression of progesterone receptor form A and B mRNAs in gynecologic malignant tumors. Tumour Biol 16:254-260
43. Arnett-Mansfield RL, deFazio A, Wain GV, Jaworski RC, Byth K, Mote PA, Clarke CL 2001 Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 61:4576-4582
44. Kumar NS, Richer J, Owen G, Litman E, Horwitz KB, Leslie KK 1998 Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: Implications for unopposed estrogen action. Cancer Res 58:1860-1865
45. Hoekstra AV, Ward EC, Hardt JL, Lurain JR, Singh DK, Buttin BM, Schink JC, Kim JJ, Chemosensitization of endometrial cancer cells through AKT inhibition involves FOXO1. Gyn Oncol, in press
46. Powis G, Ihle N, Kirkpatrick DL 2006 Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway. Clin Cancer Res 12:2964-2966